A detailed history of Gladius Capital Management LP transactions in Abb Vie Inc. stock. As of the latest transaction made, Gladius Capital Management LP holds 6,390 shares of ABBV stock, worth $1.15 Million. This represents 0.76% of its overall portfolio holdings.

Number of Shares
6,390
Previous 6,390 -0.0%
Holding current value
$1.15 Million
Previous $1.26 Million -0.0%
% of portfolio
0.76%
Previous 0.76%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$163.84 - $199.33 $352,092 - $428,360
2,149 Added 50.67%
6,390 $1.26 Million
Q2 2024

Jul 18, 2024

BUY
$154.79 - $180.76 $278,312 - $325,006
1,798 Added 73.6%
4,241 $727,000
Q1 2024

May 14, 2024

BUY
$159.82 - $182.1 $390,440 - $444,870
2,443 New
2,443 $444,000
Q3 2023

Dec 18, 2023

BUY
$133.59 - $154.65 $461,553 - $534,315
3,455 Added 64.11%
8,844 $1.32 Million
Q3 2023

Oct 10, 2023

BUY
$133.59 - $154.65 $461,553 - $534,315
3,455 Added 64.11%
8,844 $1.32 Million
Q2 2023

Dec 18, 2023

SELL
$132.51 - $164.9 $457,822 - $569,729
-3,455 Reduced 39.07%
5,389 $726,000
Q2 2023

Aug 08, 2023

BUY
$132.51 - $164.9 $481,276 - $598,916
3,632 Added 206.72%
5,389 $727,000
Q1 2023

Dec 18, 2023

SELL
$144.61 - $166.54 $1.02 Million - $1.18 Million
-7,087 Reduced 80.13%
1,757 $280,000
Q1 2023

May 09, 2023

SELL
$144.61 - $166.54 $137,813 - $158,712
-953 Reduced 35.17%
1,757 $281,000
Q4 2022

Dec 18, 2023

SELL
$138.31 - $165.87 $848,393 - $1.02 Million
-6,134 Reduced 69.36%
2,710 $438,000
Q4 2022

Feb 02, 2023

SELL
$138.31 - $165.87 $879,236 - $1.05 Million
-6,357 Reduced 70.11%
2,710 $438,000
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $989,664 - $1.14 Million
7,374 Added 435.56%
9,067 $1.22 Million
Q2 2022

Aug 10, 2022

SELL
$137.62 - $174.96 $732,826 - $931,662
-5,325 Reduced 75.88%
1,693 $260,000
Q1 2022

Apr 29, 2022

BUY
$131.98 - $163.75 $696,854 - $864,600
5,280 Added 303.8%
7,018 $1.14 Million
Q4 2021

Feb 08, 2022

BUY
$107.43 - $135.93 $107,537 - $136,065
1,001 Added 135.82%
1,738 $236,000
Q3 2021

Nov 12, 2021

BUY
$106.4 - $120.78 $32,132 - $36,475
302 Added 69.43%
737 $80,000
Q2 2021

Aug 06, 2021

BUY
$105.21 - $117.21 $45,766 - $50,986
435 New
435 $49,000
Q4 2020

Feb 09, 2021

SELL
$80.49 - $108.67 $249,840 - $337,311
-3,104 Closed
0 $0
Q3 2020

Nov 12, 2020

BUY
$85.91 - $100.83 $266,664 - $312,976
3,104 New
3,104 $272,000
Q1 2020

May 07, 2020

SELL
$64.5 - $97.79 $27,477 - $41,658
-426 Closed
0 $0
Q4 2019

Feb 13, 2020

SELL
$72.13 - $90.25 $395,633 - $495,021
-5,485 Reduced 92.79%
426 $38,000
Q3 2019

Nov 14, 2019

SELL
$62.98 - $75.72 $21,980 - $26,426
-349 Reduced 5.58%
5,911 $448,000
Q2 2019

Aug 13, 2019

SELL
$65.7 - $83.98 $1.31 Million - $1.67 Million
-19,882 Reduced 76.05%
6,260 $460,000
Q1 2019

May 15, 2019

SELL
$77.14 - $90.79 $99,819 - $117,482
-1,294 Reduced 4.72%
26,142 $0
Q4 2018

Feb 15, 2019

BUY
$77.85 - $96.01 $1.89 Million - $2.33 Million
24,291 Added 772.37%
27,436 $2.53 Million
Q3 2018

Nov 15, 2018

SELL
$88.91 - $98.84 $406,051 - $451,402
-4,567 Reduced 59.22%
3,145 $0
Q2 2018

Aug 13, 2018

BUY
$89.78 - $106.23 $692,383 - $819,245
7,712 New
7,712 $715,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Gladius Capital Management LP Portfolio

Follow Gladius Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gladius Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Gladius Capital Management LP with notifications on news.